Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 5/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315644 | 1.00 | CYP2A6 (0.37) | CYP2A6INPPL1PIK3CDCHRNB1CHRNB2 | |
| SCHEMBL2142297 | 0.88 | CHRNB2 (0.40) | INPPL1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2142301 | 0.88 | CHRNB2 (0.40) | INPPL1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL315299 | 0.86 | CYP19A1 (0.33) | GSK3B | |
| SCHEMBL315298 | 0.86 | CYP19A1 (0.33) | GSK3B | |
| SCHEMBL314605 | 0.86 | CYP11B1 (0.36) | CYP2A6INPPL1CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL2413305 | 0.86 | NPC1 (0.38) | CYP2A6PIK3CDERN1 | |
| SCHEMBL2413310 | 0.86 | NPC1 (0.38) | CYP2A6PIK3CDERN1 | |
| SCHEMBL314606 | 0.86 | CYP11B1 (0.36) | CYP2A6INPPL1CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL315871 | 0.85 | CHRNB2 (0.36) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
| EP-2066683-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037922-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | CYP2A6 158/4885INPPL1 298/4885PIK3CD 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.